Harrow (HROW) Stock Analysis & Forecast

Last earnings call, Aug 10, 2026 AI summary

What they said

Harrow reported Q2 2026 results and provided commercial and pipeline updates. Revenue for Q2 was $70.7 million (up 11% YoY, ~60% sequentially), bringing first-half revenue to approximately $115 million. VEVYE drove strong growth with quarterly revenue of $29.4 million (up ~58% YoY). IHEEZO showed record unit demand but reported revenue lagged due to distributor channel inventory; IHEEZO generated $15.6 million primarily from wholesaler stocking of a new 5-pack. The compounded portfolio contributed $14.6 million; specialty portfolio and TRIESENCE ~ $11 million. GAAP gross margin was 71% in Q2, with management expecting gross margins to trend toward the high-70s in H2 due to IHEEZO normalization, VEVYE growth, and improved mix. SG&A was $53.3 million; adjusted EBITDA was negative $1.2 million. Management emphasized that H1 was spent building commercial capacity and that H2 is focused on converting demand into revenue and profitability. Harrow reiterated full-year guidance and reiterated a 2027 exit-rate goal (~$250M) that management believes is achievable with current assets (TYRVAYA is additive). They announced a pending acquisition of TYRVAYA (from Viatris) expected to add experienced dry-eye reps and >$30M revenue contribution when fully integrated, and they assume exclusivity through 2034 for planning. R&D progress: MELT-300 (procedural sedation) has a pre-NDA meeting scheduled early Q4 and NDA targeted H1 2027 with potential approval in H1 2028; MELT-210 (pediatric) is advancing; QUEL (IHEEZO clinical trial) is ongoing with enrollment completing later this year. Management stressed improved pricing actions (VEVYE business rule changes), a PBM top-3 commercial coverage win for VEVYE commercial lives, a sampling program replacing an expensive $0 first-fill model, and inventory normalization for compounded products. Investor Q&A showed management confidence on commercialization, PBM coverage, product synergy (VEVYE + TYRVAYA), and demand trends, while acknowledging remaining integration costs for TYRVAYA, inventory-related revenue timing, and the need to execute commercially to hit H2 targets.

Guidance

Reiterated full-year guidance (no numerical change stated on the call). Specific guidance items mentioned: - Expectation that gross margins will trend toward the high-70s in the second half of 2026. - Base SG&A dollars expected to remain approximately flat with Q2 levels for the balance of the year (excluding additional headcount tied to TYRVAYA transaction). - TYRVAYA (pending close) expected to contribute more than $30 million of revenue (timing dependent on close); company assumes product exclusivity through 2034 for modeling. - Prior guidance: compounded portfolio revenue guide of $60–65 million for the year remains in place (March guidance reiterated). - Company reiterated a previously stated 2027 exit-rate target of ~$250 million (management believes achievable with existing products, TYRVAYA is additive).

Risks flagged

Risks mentioned or implicit on the call include: - H1 revenue was lighter than expected due to VEVYE net revenue impact and distributor channel inventory—timing risk to revenue recognition. - Deal/transaction risk: TYRVAYA close is pending and many comments were hedged because Harrow does not yet own the asset. - Regulatory risk: MELT-300 and other programs require successful FDA interactions/approvals; pre-NDA and NDA timelines could shift. - Market access and reimbursement risk (PBM formulary positioning, prior authorization, co-pay utilization). - Competitive risk (biosimilars and branded competitors in ophthalmology and dry eye markets). - Execution risk: integration costs for acquisitions, ability to convert demand into revenue, and reliance on commercial execution to hit H2 goals. - Macro/third-party data undercounting issues and variability between internal and third-party data sources could obscure performance trends.